AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05321797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
Study NCT05321797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
Study NCT05321797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
Study NCT04942418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicolor hybrid ceramic laminate veneers.
Description: Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
Study NCT04942418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicolor fieldspathic ceramic laminate veneers.
Description: the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
Study NCT05816655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI plus ribociclib
Description: AI + ribociclib +/- GnRH agonist
Study NCT05748938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RD14-01
Description: ROR1 Targeted CAR-T cells
Study NCT06688318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular secretome injection therapy
Description: Intra-articular secretome injection therapy from hypoxic umbilical cord mesenchymal stem cell conditioned media
Study NCT06688513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carealth Phone App
Description: The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
Study NCT05089890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sorbact® Compress
Description: Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own.
Study NCT05089890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sorbact® Gel Dressing
Description: Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own.
Study NCT05089890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sorbact® Ribbon Gauze
Description: Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own.
Study NCT05963867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532
Study NCT05963867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-BI 764532
Description: \[89Zr\]Zr-BI 764532
Study NCT06688513 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Let's Talk: Sharing information about Family Cancer Risk
Description: An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
Study NCT06686459 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ALL-in-one radiotherapy
Description: ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
Study NCT06197425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI cures
Description: (Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
Study NCT06197425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine cures
Description: Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
Study NCT06197425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIOLOGICAL ASSESSMENT
Description: blood sample ACE markers
Study NCT06197425 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BIOLOGICAL ASSESSMENT
Description: blood sample ACE markers
Study NCT06686459 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
Study NCT06197425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
Study NCT06633042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal BCMA-CD19 CART
Description: 1.0-4.0×10\^6 CAR-T cells/kg
Study NCT06694610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-pulmonary vein ablation group
Description: In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
Study NCT06694610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: only pulmonary vein ablation group
Description: In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
Study NCT06694376 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study NCT06686368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-DROP MGD
Description: All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
Study NCT06686368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theloze Duo
Description: All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
Study NCT06197425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
Study NCT06197425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic-abdomino-pelvic scan or MRI
Description: Thoracic-abdomino-pelvic scan or MRI
Study NCT06686368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Complete PF
Description: All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
Study NCT06197425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic-abdomino-pelvic scan or MRI
Description: Thoracic-abdomino-pelvic scan or MRI
Study NCT06686524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD19 UCAR-T cells
Description: A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
Study NCT06689371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (Dry Needling)
Description: The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.
Study NCT06689371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B (Dry cupping)
Description: Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.
Study NCT06689371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C (control)
Description: will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
Study NCT06695676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Global Longitudinal Strain
Description: Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
Study NCT06687473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-based susceptibility-guided treatment
Description: The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
Study NCT05202171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization Exercise
Description: Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
Study NCT05202171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
Study NCT05370144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
Study NCT04628975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transillumination dispositif
Description: infrared light
Study NCT04816201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
Study NCT04816201 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
Study NCT05016284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JW-100
Description: Cosmetic CBD cream (JW-100)
Study NCT05016284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucrisa
Description: Topical EUCRISA®, Pfizer
Study NCT05832021 — intervention group
Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation (under WALANT)
Description: Open reduction and internal fixation with volar Henry approach under WALANT.
Study NCT05832021 — intervention group
Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation (under peripheral nerve block)
Description: Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
Study NCT05343481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
Study NCT05343481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
Study NCT05343481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody
Study NCT05764720 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Adaptive External Beam Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study NCT05357807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RYGB
Description: Roux-en-Y Gastric bypass
Study NCT05357807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pouch RYGB
Description: Roux-en-Y gastric bypass with an extended pouch
Study NCT05357807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Banded extended pouch RYGB
Description: Roux-en-Y gastric bypass with a banded extended pouch
Study NCT05547802 — intervention group
Intervention type: BIOLOGICAL
Intervention: BBIBP-CorV and/or BNT162b2 vaccine
Description: Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
Study NCT06492941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin bound)
Description: Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
Study NCT06492941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was human blood albumin without the active ingredient docetaxel
Study NCT06492941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
Study NCT06492941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
Study NCT06229886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of positive-end-expiratory pressure
Description: Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
Study NCT05012423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral capsules.
Study NCT05012423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC0509
Description: ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
Study NCT05012423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be given orally during each dosing day.
Study NCT05012423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC0509
Description: ECC0509 1 mg and 10 mg capsules
Study NCT04752540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: single oral dose
Study NCT04752540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olorofim
Description: single oral dose
Study NCT05274776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS calculator
Description: For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
Study NCT06097195 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioEP
Description: When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
Study NCT05795465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn-1124
Description: Intravenous infusion
Study NCT05795465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 (I x S x S x F)
Description: Experimental message: Individual x Safety x Storytelling x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 (O x S x S x F)
Description: Experimental message: Organization x Safety x Storytelling x Factual
Study NCT04482855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: Low-level laser therapy
Study NCT03787290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: participants will receive a single subcutaneous injection of tocilizumab (162 mg)
Study NCT03787290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: participants will receive a single subcutaneous injection of saline
Study NCT03787290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Hyperthermia
Description: subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
Study NCT03787290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia
Description: subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Proton pump inhibitor
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Proton pump inhibitor
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication
Study NCT05419674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05050370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief messaging and personalized support
Description: Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
Study NCT05205486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 3gm for Injection USP and Dextrose Injection USP
Description: Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing >/= 120 kg
Study NCT04629144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity.